Dr Cohen on Teclistamab Plus Talquetamab in R/R Multiple Myeloma
June 3rd 2023Yael Cohen, MD, discusses primary efficacy findings from the phase 1/2 RedirecTT-1 trial, which is investigating the combination of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.
Read More